Loading clinical trials...
Loading clinical trials...
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Nivolumab
Ipilimumab
Locations
35
United States
Local Institution - 0006
Springdale, Arkansas, United States
Local Institution - 0001
New Haven, Connecticut, United States
Local Institution - 0005
Jacksonville, Florida, United States
Local Institution - 0009
Atlanta, Georgia, United States
Local Institution - 0003
St Louis, Missouri, United States
Local Institution - 0038
The Bronx, New York, United States
Start Date
March 29, 2017
Primary Completion Date
February 17, 2022
Completion Date
April 24, 2023
Last Updated
May 20, 2024
NCT06043817
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT06476808
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions